A comparison of two biomaterial carriers for osteogenic protein-1 (BMP-7) in an ovine critical defect model.

Critical size defects in ovine tibiae, stabilised with intramedullary interlocking nails, were used to assess whether the addition of carboxymethylcellulose to the standard osteogenic protein-1 (OP-1/BMP-7) implant would affect the implant's efficacy for bone regeneration. The biomaterial carriers were a 'putty' carrier of carboxymethylcellulose and bovine-derived type-I collagen (OPP) or the standard with collagen alone (OPC). These two treatments were also compared to "ungrafted" negative controls. Efficacy of regeneration was determined using radiological, biomechanical and histological evaluations after four months of healing. The defects, filled with OPP and OPC, demonstrated radiodense material spanning the defect after one month of healing, with radiographic evidence of recorticalisation and remodelling by two months. The OPP and OPC treatment groups had equivalent structural and material properties that were significantly greater than those in the ungrafted controls. The structural properties of the OPP- and OPC-treated limbs were equivalent to those of the contralateral untreated limb (p > 0.05), yet material properties were inferior (p < 0.05). Histopathology revealed no residual inflammatory response to the biomaterial carriers or OP-1. The OPP- and OPC-treated animals had 60% to 85% lamellar bone within the defect, and less than 25% of the regenerate was composed of fibrous tissue. The defects in the untreated control animals contained less than 40% lamellar bone and more than 60% was fibrous tissue, creating full cortical thickness defects. In our studies carboxymethylcellulose did not adversely affect the capacity of the standard OP-1 implant for regenerating bone.

[1]  J. Nemzek,et al.  Retroviral Transmission in Bone Allotransplantation: The Effects of Tissue Processing , 1996, Clinical orthopaedics and related research.

[2]  W. Enneking,et al.  Retrieved Human Allografts: A Clinicopathological Study , 2001, The Journal of bone and joint surgery. American volume.

[3]  N. Passuti,et al.  Histological features of large bone allografts. , 1996, The Journal of bone and joint surgery. British volume.

[4]  Henry C. Vasconez,et al.  Enhancement of Bone Growth by Sustained Delivery of Recombinant Human Bone Morphogenetic Protein-2 in a Polymeric Matrix , 2001, Pharmaceutical Research.

[5]  W. Lew,et al.  Osteogenic protein‐1 induced bone formation in an infected segmental defect in the rat femur , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[6]  D. Garry,et al.  Fractures in large-segment allografts. , 1993, The Journal of bone and joint surgery. American volume.

[7]  P. Aspenberg,et al.  Fibroblast growth factor stimulates bone formation. Bone induction studied in rats. , 1989, Acta orthopaedica Scandinavica.

[8]  B. Eppley,et al.  Negatively charged resins stimulate bone formation in subperiosteal sites in rats. The effect of age. , 1994, Clinical Orthopaedics and Related Research.

[9]  P. Giunchedi,et al.  Enhancement of Ursodeoxycholic Acid Bioavailability by Cross‐linked Sodium Carboxymethyl Cellulose , 2000, The Journal of pharmacy and pharmacology.

[10]  E. E. Johnson,et al.  One-stage lengthening of femoral nonunion augmented with human bone morphogenetic protein. , 1998, Clinical orthopaedics and related research.

[11]  M. Chapman,et al.  Morbidity at bone graft donor sites. , 1989, Journal of orthopaedic trauma.

[12]  K. Heiple,et al.  The effect of histocompatibility matching on canine frozen bone allografts. , 1983, The Journal of bone and joint surgery. American volume.

[13]  S. Cook Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. , 1999, Orthopedics.

[14]  A. Reddi,et al.  Collagenous bone matrix-induced endochondral ossification hemopoiesis , 1976, The Journal of cell biology.

[15]  Eric E. Johnson,et al.  Human Bone Morphogenetic Protein Allografting for Reconstruction of Femoral Nonunion , 2000, Clinical orthopaedics and related research.

[16]  K. Heiple,et al.  Immune responses of rats to frozen bone allografts. , 1983, The Journal of bone and joint surgery. American volume.

[17]  G. Zych,et al.  Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions: A Prospective, Randomized Clinical Trial Comparing rhOP-1 with Fresh Bone Autograft* , 2001, The Journal of bone and joint surgery. American volume.

[18]  M. Gebhardt,et al.  Fractures of allografts. Frequency, treatment, and end-results. , 1990, The Journal of bone and joint surgery. American volume.

[19]  F. Bahia,et al.  Evaluation of carboxymethylcellulose, hydroxypropylmethylcellulose, and aluminum hydroxide as potential carriers for rhBMP-2. , 2001, Journal of biomedical materials research.

[20]  A. Brooks Bone in clinical orthopaedics.: Edited by Geoff Sumner-Smith. Pp 492. Dübendorf: AO Publishing, 2002. ISBN: 3-13-125721-0. €159.00. , 2003 .

[21]  E. Chao,et al.  The effect of recombinant human osteogenic protein‐1 (bone morphogenetic protein‐7) impregnation on allografts in a canine intercalary bone defect , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  W. Enneking,et al.  Observations on massive retrieved human allografts. , 1991, The Journal of bone and joint surgery. American volume.

[23]  S D Cook,et al.  The Effect of Osteogenic Protein-1 on the Healing of Segmental Bone Defects Treated with Autograft or Allograft Bone , 2001, The Journal of bone and joint surgery. American volume.

[24]  W. Hutton,et al.  Delivery of Recombinant Human Bone Morphogenetic Protein-2 Using a Compression-Resistant Matrix in Posterolateral Spine Fusion in the Rabbit and in the Non-Human Primate , 2002, Spine.

[25]  J. Key THE EFFECT OF A LOCAL CALCIUM DEPOT ON OSTEOGENESIS AND HEALING OF FRACTURES , 1934 .

[26]  V. Goldberg,et al.  Natural history of autografts and allografts. , 1987, Clinical orthopaedics and related research.

[27]  D. B. Duncan MULTIPLE RANGE AND MULTIPLE F TESTS , 1955 .

[28]  S. Bulstra,et al.  Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect , 1999 .

[29]  R. Cancedda,et al.  Cell condensation in chondrogenic differentiation. , 1992, Experimental cell research.

[30]  A. van Lingen,et al.  New Segmental Long Bone Defect Model in Sheep: Quantitative Analysis of Healing with Dual Energy X-Ray Absorptiometry , 2000 .

[31]  W. Enneking,et al.  Allograft Bone Decreases in Strength In Vivo over Time , 2005, Clinical orthopaedics and related research.

[32]  H. Mankin,et al.  Clinical experience with allograft implantation. The first ten years. , 1983, Clinical orthopaedics and related research.

[33]  S. Cook,et al.  Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental bone defects. , 1998, Journal of orthopaedic trauma.

[34]  S. Vukicevic,et al.  Orthopaedic applications of osteogenic protein-1 (BMP-7) , 2001, International Orthopaedics.

[35]  L. Resnick,et al.  Human Immunodeficiency Virus Cultured From Bone: Implications for Transplantation , 1990, Clinical orthopaedics and related research.

[36]  S. Cook,et al.  Healing Course of Primate Ulna Segmental Defects Treated With Osteogenic Protein-1 , 2002, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[37]  N Verbeke,et al.  Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. , 2000, International journal of pharmaceutics.